Pfizer Inc
PFE: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$61.00 | Plfwk | Vqrdvgtz |
Pfizer's Diverse Portfolio of Drugs and Vaccines Supports Steady Cash Flows
Business Strategy and Outlook
Pfizer's foundation remains solid, based on strong cash flows generated from a basket of diverse drugs. The company's large size confers significant competitive advantages in developing new drugs. This unmatched heft, combined with a broad portfolio of patent-protected drugs, has helped Pfizer build a wide economic moat around its business.